Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Pfizer Says Phase 3 Study PROFILE 1007 Evaluating XALKORI Met Primary Goal

Pfizer Inc. (PFE: Quote) said that the PROFILE 1007 study achieved its primary endpoint, showing that XALKORI (crizotinib) significantly improved progression-free survival when compared with pemetrexed or docetaxel, in previously treated patients with anaplastic lymphoma kinase, or ALK-positive advanced non-small cell lung cancer, or NSCLC.

According to the company, PROFILE 1007 is the first randomized Phase 3 study in ALK-positive advanced NSCLC patients.

"These results are important because they demonstrate, for the first time, that XALKORI is superior to standard chemotherapy in prolonging survival without progression in patients with previously-treated ALK-positive advanced NSCLC," said Mace Rothenberg, senior vice president of Clinical Development and Medical Affairs for Pfizer's Oncology Business Unit. "This study provides further support for the precision medicine approach to drug development being taken at Pfizer by demonstrating how knowledge about the underlying genetic abnormalities within a cancer can be used to improve the standard of care for that disease."

Pfizer noted that the adverse events observed on crizotinib and chemotherapy in PROFILE 1007 were generally consistent with their respective known adverse event profiles. Full efficacy and safety data from the study would be presented at an upcoming medical congress.

Register
To receive FREE breaking news email alerts for Pfizer Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Specialty drugmaker Horizon Pharma plc (HZNP) on Friday managed to redomicile itself as an entity incorporated in Ireland following the completion of its $660 million acquisition of Vidara Therapeutics International plc. The deal will help it avoid paying the high rate of U.S. corporate taxes. The... Stocks showed a lack of direction over the course of the trading day on Friday after failing to sustain an initial upward move. Despite the choppy trading, the Dow once again managed to end the session at a new record closing high. The major averages turned in a mixed performance on the day. President Barack Obama delivered a statement Thursday evening thanking members of Congress for voting to approve legislation granting the U.S. military the authority to train and arm moderate Syrian rebels fighting against the terrorist group known as the Islamic State.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.